Vaccinex Inc.

5.41+0.8100+17.61%Vol 5321Y Perf -27.56%
Nov 19th, 2019 09:43
BID4.61 ASK5.50
Open5.41 Previous Close5.00
Pre-Market- After-Market-
 - -%  - -%
Target Price
22.00 
Analyst Rating
Strong Buy 1.00
Potential %
378.26 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/100/100 
Income Ranking
 —    -
Market Cap (M)80 
Earnings Rating
Sell
Price Range Ratio 52W %
40.43 
Earnings Date
12th Nov 2019

Today's Price Range

5.415.41

52W Range

3.328.49

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-14.81%
1 Month
-23.21%
3 Months
-8.00%
6 Months
-33.33%
1 Year
-27.56%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
VCNX5.410.810017.61
AAPL267.240.14000.05
GOOG1 321.180.48000.04
MSFT150.440.10000.07
XOM68.33-0.1900-0.28
WFC54.100.10000.19
JNJ134.930.10000.07
FB199.371.97001.00
GE11.38-0.0600-0.52
JPM130.48-0.1400-0.11
Earnings HistoryEstimateReportedSurprise %
Q03 2019-0.53-0.56-5.66
Q02 2019-0.70-0.77-10.00
Q01 2019-0.68-0.79-16.18
Q03 2018-0.58-0.93-60.34
----
----
----
----
Earnings Per EndEstimateRevision %Trend
12/2019 QR-0.520.00-
12/2019 QR-0.52-36.84Negative
12/2019 FY-2.600.00-
12/2020 FY-2.040.00-
Next Report Date-
Estimated EPS Next Report-0.53
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume532
Shares Outstanding (K)14 863
Trades Count1
Dollar Volume2 708
Avg. Volume8 517
Avg. Weekly Volume980
Avg. Monthly Volume2 665
Avg. Quarterly Volume5 405
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Vaccinex Inc.

Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its lead product candidate VX15 is in clinical development for the treatment of NSCLC, osteosarcoma and Huntington's disease and additional product candidates VX5 and VX25 are in earlier stages of development.

CEO: Maurice Zauderer

Teplephone: +1 585 271-2700

Address: 1895 Mount Hope Avenue, Rochester 14620, NY, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

44%56%

News

Stocktwits